Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) based on cardiac echocardiography (ECHO) or multi-gated acquisition (MUGA)
Left ventricular ejection fraction >= 50% by transthoracic echocardiography or multi-gated acquisition scan (MUGA) within 28 days prior to the first dose of the study drug
Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction of > 50% on baseline echocardiography or multi-gated acquisition (MUGA) scan
Participants must have adequate cardiac function, e.g. left ventricular ejection fraction (LVEF) of > 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); corrected QT interval (QTc) < 470ms
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography, multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI); no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (within 28 days of study registration)
Left ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning)
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiography (ECHO) or radionuclide ventriculogram (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Left ventricular ejection fraction (LVEF) >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
Patient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of TVB 2640 and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) of >= 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) < 470 msec on screening electrocardiogram (EKG)
Left ventricular ejection fraction (LVEF) of lesser than [<] 50 percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screening
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Baseline (pre-HCT) multi-gated acquisition (MUGA) or echocardiography (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of normal (LLN) of the institutional normal
Left ventricular ejection fraction (LVEF) < 50 as determined by multi gated acquisition scan (MUGA) scan or echocardiography (ECHO)
Cardiac function >= international lower limit of normal (ILLN), e.g., left ventricular ejection fraction (LVEF) of > 50% as assessed by multi gated acquisition scan (MUGA) or echocardiography (ECHO), corrected QT interval (QTc) < 470 ms
Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiography (ECHO)/ multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physician
Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) greater than or equal to 50%) at baseline as determined by echocardiography.
Left ventricular ejection fraction equal to or greater than normal within 1 month of enrollment; echocardiography (ECHO) scans must be used throughout the study
Left ventricular ejection fraction must be evaluated by nuclear medicine scan or echocardiography and measure >= 50%
No cardiac (left ventricular ejection fraction [LVEF] > 50% by multigated acquisition scan [MUGA] or three-dimensional echocardiography [TTE]; if LVEF > 40% but < 50% by MUGA or TTE MUST HAVE cardiology evaluation and clearance for ASCT)
Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatment
No active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if multi gated acquisition (MUGA) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%
Left ventricular ejection fraction ? 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure
Within 14 days of study registration (30 days for pulmonary and cardiac): left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multigated acquisition (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Presence of left ventricular thrombus as documented by echocardiography or left ventriculogram
Left ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or multi-gated acquisition scan (MUGA); or current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or decrease of greater than 15% attributable to past trastuzumab or pertuzumab therapy
CLINICAL/LABORATORY CRITERIA: Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiography (ECHO) or multi-gated acquisition scan (MUGA) within 42 days prior to registration
Left ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan.
Cardiac ejection fraction >= 50% by echocardiography or multi gated acquisition (MUGA) (when left ventricular ejection fraction [LVEF] expressed as a range, at least the upper limit should include 50%)
Left ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographic suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Intraventricular septal (IVS) thickness =< 25 mm (as determined by 2-dimensional [2D] echocardiography or cardiac magnetic resonance imaging [MRI]) (ejection fraction may also be assessed by a multi-gated acquisition [MUGA])
Cardiac ejection fraction >= 45% by echocardiography (transthoracic echocardiography) or multi gated acquisition scan (MUGA) scan
Left ventricular ejection fraction within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) must be >= the lower limit of normal (LLN) per institutional standards by either echocardiography or radionuclide-based multiple gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% (as assessed by echocardiography [ECHO] or multigated acquisition [MUGA]) documented within 4 weeks prior to first dose of study treatment
Adequate cardiac function (left ventricular ejection fraction [LVEF] ?50% measured by echocardiography or multi-gated acquisition [MUGA] scan)
Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multi gated acquisition (MUGA) scan or echocardiography
Baseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Left ventricular ejection fraction (LVEF) >= 45 % (by multigated acquisition scan [MUGA] or echocardiography)
Baseline of Left Ventricular Ejection Fraction (LVEF) ?50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality
Left ventricular ejection fraction >= 40%, assessed within 3 months prior to study day 1, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographical suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal
Left ventricular ejection fraction (LVEF) less than 50 percent as assessed by echocardiography (or multi-gated acquisition) performed at screening
Normal (greater than 50%) left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiography
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by echocardiography or multigated acquisition (MUGA) scan
Has a pre-treatment transthoracic echocardiography (TTE) showing a calculated left ventricular ejection fraction of less than 50%
Left ventricular ejection fraction (LVEF) >50% on echocardiography or multiple-gate acquisition (MUGA) scan.
Left ventricular ejection fraction (LVEF) by echocardiography (ECHO) or multiplegated acquisition (MUGA) within normal range (according to institutional standards).
Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiography or MUGA scan performed at Screening
